BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Mirus Bio Corporation Announces Delivery Technology Breakthrough for RNAi Therapeutics


7/27/2007 9:42:10 AM

MADISON, Wis., July 27 /PRNewswire/ -- Researchers at Mirus Bio Corporation have developed a technique to target specific cells with a genetic "silencing switch," known as RNA interference (RNAi), which blocks the production of disease-causing proteins inside those cells. In a first proof-of-concept demonstration, Mirus scientists targeted liver cells and switched off their ability to produce "bad" cholesterol. This delivery platform could also be used as a foundation for RNAi therapeutics to disable cancer cells, viruses, and genes that cause other metabolic diseases, among a broad range of potential applications. Details of this breakthrough have just been published in the online Early Edition of the Proceedings of the National Academy of Sciences under the title "Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes". Mirus Bio, which was founded in 1995, specializes in nucleic acid chemistry and delivery systems for RNAi- and gene-based therapies.

Read at press release

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES